927066--2/28/2007--DAVITA

related topics

{regulation, government, change}

{cost, contract, operation}

{cost, operation, labor}

{debt, indebtedness, cash}

{customer, product, revenue}

{tax, income, asset}

{product, liability, claim}

{gas, price, oil}

{acquisition, growth, future}

{provision, law, control}

{product, candidate, development}

{investment, property, distribution}

{loss, insurance, financial}

If the average rates that commercial payors pay us decline significantly, it would have a material adverse effect on our revenues, earnings and cash flows. If the number of patients with higher-paying commercial insurance declines, then our revenues, earnings and cash flows would be substantially reduced. Future declines, or the lack of further increases, in Medicare payment rates would reduce our revenues, earnings and cash flows. Changes in the structure of, and payment rates under, the Medicare ESRD program could substantially reduce our revenues, earnings and cash flows. Changes in state Medicaid programs or payment rates could reduce our revenues, earnings and cash flows. Delays in state Medicare and Medicaid certification of our dialysis centers could adversely affect our revenues, earnings and cash flows. Changes in clinical practices and payment rates or rules for EPO and other pharmaceuticals could substantially reduce our revenues, earnings and cash flows. Changes in EPO pricing and the use and marketing of alternatives to EPO could materially reduce our revenues, earnings and cash flows and affect our ability to care for our patients. The investigation related to the subpoena we received on March 4, 2005 from the U.S. Attorney s Office for the Eastern District of Missouri could result in substantial penalties against us. The investigation related to the subpoena we received on October 25, 2004 from the U.S. Attorney s Office for the Eastern District of New York could result in substantial penalties against us. If we fail to adhere to all of the complex government regulations that apply to our business, we could suffer severe consequences that would substantially reduce our revenues, earnings and cash flows. If our joint ventures were found to violate the law, we could suffer severe consequences that would have a material adverse effect on our revenues, earnings and cash flows. There are significant estimating risks associated with the amount of dialysis revenue that we recognize and if we are unable to accurately estimate our revenue, it could impact the timing of our revenue recognition or have a significant impact on our operating results. We may be subject to liability claims for damages and other expenses not covered by insurance that could reduce our earnings and cash flows. If businesses we acquire have liabilities that we are not aware of, we could suffer severe consequences that would substantially reduce our revenues, earnings and cash flows. If the ancillary services we provide or the strategic initiatives we invest in are ultimately unsuccessful, we may have to write off our investment in one or more of these activities. If a significant number of physicians were to cease referring patients to our dialysis centers, whether due to regulatory or other reasons, our revenues, earnings and cash flows would be substantially reduced. The level of our current and future debt could have an adverse impact on our business. We will require a significant amount of cash to service our indebtedness. Our ability to generate cash depends on many factors beyond our control. If the current shortage of skilled clinical personnel continues or if we experience a higher than normal turnover rate, we may experience disruptions in our business operations and increases in operating expenses. The integration of DVA Renal Healthcare s clinical, billing and collection systems into our operations is significant and the failure to successfully integrate the systems could have a material adverse effect on our revenues, cash flows and operating results. If DVA Renal Healthcare does not comply with its corporate integrity agreement, or DVA Renal Healthcare otherwise has failed or fails to comply with government regulations applicable to its operations, we could be subject to additional penalties and otherwise may be materially harmed. Our alliance and product supply agreement with Gambro Renal Products Inc. may limit our ability to achieve cost savings with respect to products and equipment we are required to purchase under this agreement. Our ability to effectively provide the services we offer could be negatively impacted if certain of our suppliers are unable to meet our needs, which could substantially reduce our revenues, earnings and cash flows. Provisions in our charter documents, compensation programs and Delaware law may deter a change of control that our stockholders would otherwise determine to be in their best interests.

Full 10-K form ▸

927066--2/28/2007--DAVITA_INC